The DOI matches its Crossref record.
Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus
Open accessAbstract
We have proposed that the mechanisms of alloengraftment and variable acquired tolerance can be facilitated by minimum posttransplant immunosuppression. It was further suggested that the efficacy of minimalistic treatment could be enhanced by preoperative recipient conditioning with an antilymphoid antibody preparation. A total of 76 adults (38 hepatitis C virus [HCV], 38 HCV) were infused with 30 mg alemtuzumab before primary cadaveric liver transplantation and maintained afterward on daily monotherapy unless breakthrough rejection mandated additional agents. In stable patients, the intervals between tacrolimus doses were lengthened ("spaced weaning") after approximately 4 months. Eighty-four contemporaneous nonlymphoid-depleted liver recipients (58 HCV, 26 HCV) were treated with conventional postoperative immunosuppression. The overall incidence of rejection was similar with the two strategies of immunosuppression. With follow-ups of 14 to 22 months, patient and primary graft survival in HCV cases are 97% and 90%, respectively, with alemtuzumab depletion plus minimal immunosuppression versus 71% and 70%, respectively, under conventional immunosuppression. In HCV recipients, current patient and graft survival in the alemtuzumab-pretreated group are 71% and 70% versus 65% and 54%, respectively, under conventional treatment. With both strategies of immunosuppression, the adverse effect of preexisting HCV on survival parameters and graft function already was significant at the 1-year milestone, but its extent was not evident until the second year. With or without HCV, 62% of the 64 surviving lymphoid-depleted patients are on spaced immunosuppression, and four patients receive no immunosuppression. Lymphoid depletion with alemtuzumab and minimalistic maintenance immunosuppression is a practical strategy of liver transplantation in HCV recipients but not HCV recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Immunosuppression: Evolution in Practice and Trends, 1994–2004
Meier-Kriesche, H.-U., Li, S., Gruessner, R. W. G., Fung, J. J., Bustami, R. T., Barr, M. L., & Leichtman, A. B. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01270.x · Cited by 559
Self-citationTodo, S., Yamashita, K., Goto, R., Zaitsu, M., Nagatsu, A., Oura, T., Watanabe, M., Aoyagi, T., Suzuki, T., Shimamura, T., et al. (2016) · Hepatology · doi:10.1002/hep.28459 · Cited by 441
Self-citationLiver biopsy interpretation for causes of late liver allograft dysfunction
(2006) · Hepatology · doi:10.1002/hep.21280 · Cited by 359
Immunosuppression minimization vs. complete drug withdrawal in liver transplantation
Londoño, M.-C., Rimola, A., O’Grady, J., & Sanchez-Fueyo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.003 · Cited by 118
Metadata
- Authors
- Marcos, A., Eghtesad, B., Fung, J. J., Fontes, P., Patel, K., deVera, M., Marsh, W., Gayowski, T., Demetris, A. J., Gray, E. A., Flynn, B., Zeevi, A., Murase, N., & Starzl, T. E.
- Venue
- Transplantation
- Published
- 2004-10-15
- Volume
- 78
- Issue
- 7
- Pages
- 966-971
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2144606768
- Cited by
- 165
- References
- 0
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus. https://app.cochat.ai/papers/10.1097/01.tp.0000142674.78268.01
- The paper
- Marcos, A., Eghtesad, B., Fung, J. J., Fontes, P., Patel, K., deVera, M., Marsh, W., Gayowski, T., Demetris, A. J., Gray, E. A., Flynn, B., Zeevi, A., Murase, N., & Starzl, T. E. (2004). Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus. Transplantation. https://doi.org/10.1097/01.tp.0000142674.78268.01
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.